Addressing the interactions between opioid ligands and their receptors: Classic and nonclassic cases

Neuropeptides in Neuroprotection and Neuroregeneration

Volumn , Issue , 2012, Pages 229-252

  Gentilucci, Luca ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884213687     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12279     Document Type: Chapter

References (113)

1. Akiyama, K., Gee, K. W., Mosberg, H. I., Hruby, V. J., Yamamura, H. I. 1985. Characterization of [3H][2-D-penicillamine, 5-D-penicillamine]-enkephalin binding to delta opiate receptors in the rat brain and neuroblastoma-glioma hybrid cell line (NG 108-15). Proc. Natl. Acad. Sci. USA. 82: 2543-7.
2. Aldrich, J. V., McLaughlin, J. P. 2009. Peptide kappa opioid receptor ligands: potential for drug development. AAPS J. 11: 312-22.
3. Aldrich, J. V., Kulkarni, S. S., Senadheera, S. N., Ross, N. C., Reilley, K. J., Eans, S. O., Ganno, M. L., Murray, T. F., McLaughlin, J. P. 2011. Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208. Chem. Med. Chem. 6: 1739-45.
4. Ananthan, S., Zhang, W., Hobrath, J. V. 2009. Recent advances in structure-based virtual screening of G-protein coupled receptors. AAPS J. 11: 178-85.
5. Arnold, Z. S., Schiller, P. W. 2000. Optically active aromatic amino acids. Part VI. Synthesis and properties of (Leu5)-enkephalin analogues containing O-methyl-L-tyrosine1 with ring substitution at position 3'. J. Pept. Sci. 6: 280-9.
6. Bedini, A., Baiula, M., Gentilucci, L., Tolomelli, A., De Marco, R., Spampinato, S. 2010. Peripheral antinociceptive effects of the cyclic endomorphin-1 analogue c[YpwFG] in a mouse visceral pain model. Peptides. 31: 2135-40.
7. Beguin, C., Richards, M. R., Wang, Y., et al. 2005. Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues. Bioorg. Med. Chem. Lett. 15: 2761-5.
8. Bernard, D., Coop, A., MacKerell, A. D. Jr. 2003. 2D conformationally sampled pharmacophore: a ligand-based pharmacophore to differentiate δ opioid agonists from antagonists. J. Am. Chem. Soc. 125: 3101-7.
9. Bodnar, R. J. 2009. Endogenous opiates and behaviour: 2008. Peptides. 30: 2432-79.
10. Borics, A., Toth, G. 2010. Structural comparison of mu-opioid receptor selective peptides confirmed four parameters of bioactivity. J. Mol. Graph. Model. 28: 495-505.
11. Bountra, C., Munglani, R., Schmidt, W. K. 2003. Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. New York: Marcel Dekker.
12. Breivik, H. 2005. Opioids in chronic non-cancer pain, indications and controversies. Eur. J. Pain. 9: 127-30.
13. Burden, J. E., Davis, P., Porreca, F., Spatola, A. F. 1999. Synthesis and biological activities of position one and three transposed analogs of the opioid peptide YKFA. Bioorg. Med. Chem. Lett. 9: 3441-6.
14. Calderon, S. N., Coop, A. 2004. SNC 80 and related delta opioid agonists. Curr. Phar. Des. 10: 733-42.
15. Cardillo, G., Gentilucci, L., Melchiorre, P., Spampinato, S. 2000. Synthesis and binding activity of endomorphin-1 analogues containing β-amino acids. Bioorg. Med. Chem. Lett. 10: 2755-8.
16. Cardillo, G., Gentilucci, L., Qasem, A. R., Sgarzi, F., Spampinato, S. 2002. Endomorphin-1 analogues containing beta-proline are mu-opioid receptor agonists and display enhance enzymatic hydrolysis resistance. J. Med. Chem. 45: 2571-8.
17. Cardillo, G., Gentilucci, L., Tolomelli, A., Qasem, A. R., Spampinato, S., Calienni, M. 2003. Conformational analysis and µ-opioid receptor affinity of short peptides, endomorphin models in a low polarity solvent. Org. Biomol. Chem. 1: 3010-14.
18. Cardillo, G., Gentilucci, L., Tolomelli, A., et al. 2004. Synthesis and evaluation of the affinity toward l-opioid receptors of atypical, lipophilic ligands based on the sequence c[-Tyr-Pro-Trp-Phe-Gly-]. J. Med. Chem. 47: 5198-203.
19. Chaturvedi, K., Christoffers, K. H., Singh, K., Howells, R. D. 2000. Structure and regulation of opioid receptors. Biopolymers. 55: 334-46.
20. De Marco, R., Gentilucci, L., Tolomelli, A., Feddersen, S., Spampinato, S., Bedini, A., Artali, R. 2011. Novel opioid peptide agonists and antagonists. Pharm. Rep. 63: 226.
21. Doi, M., Asano, A., Komura, E., Ueda, Y. 2002. The structure of an endomorphin analogue incorporating 1-aminocyclohexane-1-carboxlylic acid for proline is similar to the β-turn of Leu-enkephalin. Biochem. Biophys. Res. Commun. 297: 138-42.
22. Dolle, R. E., Machaut, M., Martinez-Teipel, B., et al. 2004. (4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands. Bioorg. Med. Chem. Lett. 14: 3545-8.
23. Dolle, R. E., Michaut, M., Martinez-Teipel, B., Seida, P. R., Ajello, C. W., Muller, A. L., De Haven, R. N., Carroll, P. J. 2009. Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg. Med. Chem. Lett. 19: 3647-50.
24. Dosen-Micovic, L., Ivanovic, M., Micovic, V. 2006. Steric interactions and the activity of fentanyl analogs at the l-opioid receptor. Bioorg. Med. Chem. 14: 2887-95.
25. Eguchi, M. 2004. Advances in selective opioid receptoragonists and antagonists. Med. Res. Rev. 24: 182-212.
26. Eguchi, M., Shen, R. Y., Shea, J. P., Lee, M. S., Kahn, M. 2002. Design, synthesis, and evaluation of opioid analogues with non-peptidic beta-turn scaffold: enkephalin and endomorphin mimetics. J. Med. Chem. 45: 1395-8.
27. Fichna, J., do-Rego, J.-C., Kosson, P., Costentin, J., Janecka, A. 2005. Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position. Biochem. Pharmacol. 69: 179-85.
28. Fichna, J., Janecka, A., Costentin, J., do-Rego. J.-C. 2007. The endomorphin system and its evolving neurophysiological role pharmacological reviews. Pharmacol. Rev. 59: 88-123.
29. Filizola, M. Weinstein, H. 2002. Structural models for dimerization of G-protein coupled receptors: the opioid receptor homodimers. Biopolymers. 66: 317-25.
30. Fowler, C. B., Pogozheva, I. D., Lomize, A. L., LeVine, H., III, Mosberg, H. I. 2004. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints Biochemistry. 43: 15796-810.
31. Gao, Y., Liu, X., Wei, J., Zhu, B., Chena, Q., Wang, R. 2005. Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg. Med. Chem. Lett. 15: 1847-50.
32. Gentilucci, L. 2004. New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr. Topics Med. Chem. 4: 19-38.
33. Gentilucci, L., De Marco, R., Cerisoli, L. 2010. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 16: 3185-203.
34. Gentilucci, L., Squassabia, F., Artali, R. 2007. Re-discussion of the importance of ionic interactions in stabilizing ligand-opioid receptor complex and in activating signal transduction. Curr Drug Targets. 8: 185-96.
35. Gentilucci, L., Squassabia, F., De Marco, R., et al. 2008. Investigation of the interaction between the atypical agonist c[YpwFG] and MOR. FEBS J. 275: 2315-37.
36. Gentilucci, L., Tolomelli, A., Squassabia, F. 2007. Topological exploration of cyclic endomorphin-1 analogues, structurally defined models for investigating the bioactive conformation of MOR agonists. Prot. Pept. Lett. 14: 51-6.
37. Gentilucci, L., Tolomelli, A., De Marco, R., Spampinato, S., Bedini, A., Artali, R. 2011. The inverse type II β-turn on D-Trp-Phe, a pharmacophoric motif for MOR agonists. Chem. Med. Chem. 6: 1640-53.
38. Handa, B. K., Land, A. C., Lord, J.A., Morgan, B. A., Rance, M. J., Smith, C. F. 1981. Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors. Eur. J. Pharm. 70: 531-40.
39. Harding, W. W., Tidgewell, K., Byrd, N., et al. 2005. Neoclerodane diterpenes as a novel scaffold for µ opioid receptor ligands. J. Med. Chem. 48: 4765-71.
40. Heitz, J. W., Witkowski, T. A., Viscusi, E. R. 2009. New and emerging analgesics and analgesic technologies for acute pain management. Curr. Opin. Anaesthesiol. 22: 608-17.
41. Honda, M., Okutsu, H., Matsuura, T., Miyagi, T., Yamamoto, Y., Hazato, T., Ono, H. 2001. Spinorphin, an endogenous inhibitor of enkephalin-degrading enzymes, potentiates Leu-enkephalin-induced anti-allodynic and antinociceptive effects in mice. Jpn. J. Pharmacol. 87: 261-7.
42. Horvath, G. 2000. Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous mu-opioid receptor agonists. Pharmacol. Ther. 88: 437-63.
43. Hruby, V. J., Agnes, R. S. 1999. Conformation-activity relationships of opioid peptides with selective activities at opioid receptors. Biopolymers. 51: 391-410.
44. Hruby, V. J., Balse, P. M. 2000. Conformational and Topographical considerations in designing agonist peptidomimetics from peptide leads. Curr. Med. Chem. 7: 945-70.
45. In, Y., Minoura, K., Tomoo, K., et al. 2005. Structural function of C-terminal amidation of endomorphin. Conformational comparison of mu-selective endomorphin-2 with its C-terminal free acid, studied by 1H-NMR spectroscopy, molecular calculation, and X-ray crystallography. FEBS J. 272: 5079-97.
46. Janecka, A., Fichna, J., Mirowski, M., Janecki, T. 2002. Structure-activity relationship, conformation and pharmacology studies of morphiceptin analogues-selective mu-opioid receptor ligands. Mini Rev. Med. Chem. 2: 565-72.
47. Janecka, A., Kruszynski, R. 2005. Conformationally restricted peptides as tools in opioid receptor studies. Curr. Med. Chem. 12: 471-81.
48. Janecka, A. Perlikowska, R., Gach, K., Wyrebska, A., Fichna, J. 2010. Development of opioid peptide analogs for pain relief. Curr. Pharm. Des. 16: 1126-35.
49. Jiang, C. L., Xu, D., Lu, C. L., Wang, Y. X., You, Z. D., Liu, X. Y. 2000. Interleukin-2: structural and biological relatedness to opioid peptides. Neuroimmunomodulation. 8: 20-4.
50. Johnson, R. E., Fudala, P. J., Payne, R. 2005. Buprenorphine: considerations for pain management. J. Pain Sympt. Manag. 29: 297-326.
51. Kaczor, A., Matosiuk, D. 2002. Non-peptide opioid receptor ligands-recent advances. Part I-agonists. Curr. Med. Chem. 9: 1567-89.
52. Kane, B. E., Nieto, M. J., McCurdy, C. R., Ferguson, D. M. 2006. A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist. FEBS J. 273: 1966-74.
53. Kane, B. E., McCurdy, C. R., Ferguson, D. M. 2008. Toward a structure based model of salvinorin A recognition of the κ-opioid receptor. J. Med. Chem. 51: 1824-30.
54. Keller, M., Boissard, C., Patiny, L., et al. 2001. Pseudoproline-containing analogues of morphiceptin and endomorphin-2: evidence for a cis Tyr-Pro amide bond in the bioactive conformation. J. Med. Chem. 44: 3896-903.
55. Keresztes, A., Borics, A., Tóth, G. 2010. Recent advances in endomorphin engineering. Chem. Med. Chem. 5: 1176-96.
56. Kessler, H. 1982. Conformation and biological activity of cyclic peptide. Angew. Chem. Int. Ed. Engl. 21: 512-23.
57. Levac, B. A., O’Dowd, B. F., George, S. R. 2002. Oligomerization of opioid receptors: generation of novel signaling units. Curr. Opin. Pharmacol. 2: 76-81.
58. Lipkowski, A. W., Konecka, A. M., Sroczynska, I. 1982. Double enkephalins-synthesis, activity on guinea pig ileum and analgesic effect. Peptides. 3: 697-700.
59. Lipkowski, A. W., Misicka, A., Carr, D. B., Ronsisvalle, G., Kosson, D., Bonney, I. M. 2004. Neuropeptide mimetics for pain management. Pure Appl. Chem. 76: 941-50.
60. Liu, X., Kai, M., Jin, L., Wang, R. 2009. Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg. Med. Chem. Lett. 19: 5387-91.
61. Loetsch, J., Geisslinger, G. 2005. Are mu-opioid receptor polymorphisms important for clinical opioid therapy?. Trends Mol. Med. 11: 82-9.
62. Lu, Y., Nguyen, T. M., Weltrowska, G., Berezowska, I., Lemieux, C., Chung, N. N., Schiller, P. W. 2001. [2,6-Dimethyltyrosine1]-dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective κ opioid antagonists. J. Med. Chem. 44: 3048-53.
63. Lu, Y., Weltrowska, G., Lemieux, C., Chung, N. N., Schiller, P. W. 2001. Stereospecific synthesis of (2S)-2-methyl-3-(2',6'-dimethyl-4'-hydroxyphenyl)-propionic acid (Mdp) and its incorporation into an opioid peptide. Bioorg. Med. Chem. Lett. 11: 323-5.
64. McDaid, C., Maund, E., Rice, S., Wright, K., Jenkins, B., Woolacott N. 2010. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. Health Technol. Assess. 14: 1-153.
65. McFadyen, I. J., Sobczyk-Kojiro, K., Schaefer, M. J., et al. 2000. Tetrapeptide derivatives of [D-Pen(2), D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor. J. Pharmacol. Exp. Ther. 295: 960-6.
66. Manchikanti, L., Benyamin, R., Datta, S., Vallejo, R., Smith, H. 2010. Opioids in chronic noncancer pain. Expert Rev. Neurother. 10: 775-89.
67. Meunier, J. C. 1997. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur. J. Pharmacol. 340: 1-15.
68. Milligan, G. 2004. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 66: 1-7.
69. Mobarec, J. C., Sanchez, R., Filizola, M. 2009. Modern homology modeling of G-protein coupled receptors: which structural template to use?. J. Med. Chem. 52: 5207-16.
70. Montagnini, M. L., Zaleon, C. R. 2009. Pharmacological management of cancer pain. J. Opioid Manag. 5: 89-96.
71. Mosberg, H. I., Fowler, C. B. 2002. Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs. delta selectivity. J. Pept. Res. 60: 329-35.
72. Mosberg, H. I., Ho, J. C., Sobczyk-Kojiro, K. 1998. A high affinity, mu-opioid receptorselective enkephalin analogue lacking an N-terminal tyrosine. Bioorg. Med. Chem. Lett. 8: 2681-4.
73. Mosberg, H. I., Omnaas, J. R., Medzihradsky, F., Smith, C. B. 1988. Cyclic disulfide- and dithioether-containing opioid tetrapeptides: development of a ligand with enhanced delta opioid receptor selectivity and potency. Life Sci. 43: 1013-20.
74. Munro, T. A., Rizzacasa, M. A., Roth, B. L., Toth, B. A., Yan, F. 2005. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J. Med. Chem. 48: 345-8.
75. Negri, L., Melchiorri, P., Lattanzi, R. 2000. Pharmacology of amphibian opiate peptides. Peptides. 21: 1639-47.
76. Noble, F., Smadja, C., Roques, B. P. 1994. Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists. J. Pharmacol. Exp. Ther. 271: 1127-34.
77. 1] endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond. Bioorg. Med. Chem. Lett. 11: 1983-94.
78. 2, and Examination of their opioid receptor binding activities and solution conformation. Biochem. Biophys. Res. Commun. 276: 7-11.
79. Palczewski, K., Kumasaka, T., Hori, T., et al. 2000. Crystal structure of rhodopsin: a G proteincoupled receptor. Science. 289: 739-45.
80. Paterlini, M. G., Avitabile, F., Ostrowski, B. G., Ferguson, D. M., Portoghese, P. S. 2000. Stereochemical requirements for receptor recognition of the µ-opioid peptide endomorphin-1. Biophys. J. 78: 590-9.
81. Perlikowska, R., do-Rego, J. C., Cravezic, A. 2010. Synthesis and biological evaluation of cyclic endomorphin-2 analogs. Peptides. 31: 339-45.
82. Podlogar, B. L., Paterlini, M. G., Ferguson, D. M., et al. 1998. Conformational analysis of the endogenous mu-opioid agonist endomorphin-1 using NMR spectroscopy and molecular modelling. FEBS Lett. 439: 13-20.
83. Pogozheva, I. D., Lomize, A. L., Mosberg, H. I. 1998. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys. J. 75: 612-34.
84. Presland, J. 2004. G-protein-coupled receptor accessory proteins: their potential role in future drug discovery. Biochem. Soc. Trans. 32: 888-91.
85. Przewlocki, R., Przewlocka, B. 2001. Opioids in chronic pain. Eur. J. Pharmacol. 429: 79-91.
86. Raffa, R. B., Clark-Vetri, R., Tallarida, R. J., Wertheimer, A. I. 2003. Combination strategies for pain management. Exp. Opin. Pharm. 4: 1697-708.
87. Roth, B. L., Baner, K., Westkaemper, R., et al. 2002. Salvinorin A: a potent naturally occurring nonnitrogenous κ-opioid selective agonist. Proc. Natl. Acad. Sci. USA. 99: 11934-9.
88. Roumy, M., Zajac, J. 1999. Europeptide FF selectively attenuates the effects of nociceptin on acutely dissociated neurons of the rat dorsal raphe nucleus. Brain Res. 845: 208-14.
89. Ruan, H., Prasad, J. A., Lemaire, S. 2000. Non-opioid antinociceptive effects of supraspinal histogranin and related peptides: possible involvement of central dopamine D(2) receptor. Pharmacol. Biochem. Behav. 67: 83-91.
90. Sagara, T., Egashira, H., Okamura, M., Fujii, I., Shimohigashi, Y., Kanematsu, K. 1996. Ligand recognition in µ opioid receptor: experimentally based modeling of µ opioid receptor binding sites and their testing by ligand docking. Bioorg. Med. Chem. 4: 2151-66.
91. Saito, T., Hirai, H., Kim, Y. J., Kojima, Y., Matsunaga, Y., Nishida, H., Sakakibara, T., Suga, O., Sujaku, T., Kojima, N. 2002. The tryptophan isomers of the cyclic tetrapeptide CJ-15,208, reported to be a kappa opioid receptor (KOR) antagonist. J. Antibiot. 55: 847-54.
92. Schiller, P. W., Berezowska, I., Nguyen, T. M.-D., et al. 2000. Novel ligands lacking a positive charge for the delta-and mu-opioid receptors. J. Med. Chem. 43: 551-9.
93. Schiller, P. W., Weltrowska, G., Nguyen, T. M.-D., Lemieux, C., Chung, N. N., Lu, Y. 2003. Conversion of δ-, κ-, and µ-receptor selective opioid peptide agonists into δ-, κ- and µ-selective antagonists. Life Sci. 73: 691-8.
94. Shao, X., Gao, Y., Zhu, C., et al. 2007. Conformational analysis of endomorphin-2 analogs with phenylalanine mimics by NMR and molecular modeling. Bioorg. Med. Chem. 15: 3539-47.
95. Subramanian, G., Paterlini, M. G., Portoghese, P. S., Ferguson, D. M. 2000. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J. Med. Chem. 43: 381-91.
96. Teschemacher, H. 1993. Atypical opioid peptides. In Handbook of Experimental Pharmacology, 104/1, ed. A. Herz, 499-528. Berlin: Springer-Verlag.
97. Teschemacher, H. 2003. Receptor ligands derived from food proteins. Curr. Pharm. Design. 9: 1331-44.
98. Tömböly, C., Ballet, S., Feytens, D., et al. 2008. Endomorphin-2 with a beta-turn backbone constraint retains the potent mu-opioid receptor agonist properties. J. Med. Chem. 51: 173-7.
99. Vaccarino, A. L., Kastin, A. J. 2001. Endogenous opiates: 2000. Peptides. 22: 2257-328.
100. Vadivelu, N., Sinatra, R. 2005. Recent advances in elucidating pain mechanisms. Curr. Opin. Anaesthesiol. 18: 540-7.
101. Varga, E. V., Navratilova, E., Stropova, D., Jambrosic, J., Roeske, W. R., Yamamura H. I. 2004. Agonist-specific regulation of the delta-opioid receptor. Life Sci. 76: 599-612.
102. Vig, B. S., Murray, T. F., Aldrich, J. V. A. 2003. Novel N-terminal cyclic dynorphin A analogue cycloN,5 [Trp3, Trp4, Glu5] dynorphin A-(1-11)NH2 that lacks the basic N-terminus. J. Med. Chem. 46: 1279-82.
103. 1 opiate binding sites. J. Pharmacol. Exp. Ther. 224: 7-12.
104. Weltrowska, G., Chung, N. N., Lemieux, C., et al. 2010. “Carba”-analogues of fentanyl are opioid receptor agonists. J. Med. Chem. 53: 2875-81.
105. Weltrowska, G., Lu, Y., Lemieux, C., Chung, N. N., Schiller, P. W. 2004. A Novel cyclic enkephalin analogue with potent opioid antagonist activity. Bioorg. Med. Chem. Lett. 14: 4731-3.
106. Wilson, A. M., Soignier, R. D., Zadina, J. E., et al. 2000. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides. 21: 1871-4.
107. Witt, K. A., Gillespie, T. J., Huber, J. D., Egleton, R. D., Davis, T. P. 2001. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides. 22: 2329-43.
108. Wollemann, M., Benyhe, S. 2004. Non-opioid actions of opioid peptides. Life Sci. 75: 257-70.
109. Yan, F., Mosier, P. D., Westkaemper, R. B., et al. 2005. Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to κ-opioid receptors. Biochemistry. 44: 8643-51.
110. Yang, S., Yunden, J., Sonoda, S., et al. 2001. Rubiscolin, a δ-selective opioid peptide derived from plant Rubisco. FEBS Lett. 509: 213-17.
111. Zadina, J. E., Hackler, L., Ge, L.-J., Kastin, A. J. 1997. A potent and selective endogenous agonist for the mu-opiate receptor. Nature. 386: 499-502.
112. Zhang, Y., Sham, Y. Y., Rajamani, R., Gao, J., Portoghese, P. S. 2005. Homology Modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system. Chem. Bio. Chem. 6: 853-9.
113. 2, display partial agonist potency but significant antinociception. Life Sci. 77: 1155-65.